Introduction: Empirical cohort have evidenced that central adiposity is the strongest modifiable risk factor for T2DM, however most studies neglect the absolute measures including visceral fat area (VFA) and subcutaneous fat (SFA). This study aims to analyze the strength of association between FPG, 2hPPG, HbA1c and nine anthropometrics measures, to explore the best indicator for hyperglycemic risks.
Methods: Analyses were based on the data from the Pinggu Metabolic Disease study in 2013-2014. Excluded participants with self-reported DM, dyslipidemia and hyperuricemia, 2940 were included. Anthropometrics, VFA and SFA were measured. Logistic regression was used to find the association between per standard increase and risk for high FPG (≥7.0 mmol/L), 2hPPG (≥11.1 mmol/L), HbA1c (≥6.5%).
Results: Higher VFA and SFA were associated with higher FPG, 2hPPG and HbA1c after adjusting for other covariates. The strongest association was waist to hip ratio (WHR) for FPG and 2hPPG, and waist circumference (WC) for HbA1c. The strength of association between SFA, VFA and FPG, 2hPPG and HbA1c was less than WHR and WC. VSR showed a comparably weak strength of association. See Figure for detail result.
F. Zhang: None. Y. Li: None. Y. Zhao: None. X. Zhou: None. L. Ji: Advisory Panel; Self; AstraZeneca. Consultant; Self; AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Merck KGaA, Merck Sharp & Dohme Corp., Novartis AG, Novo Nordisk A/S, Roche Pharma, Sanofi, Takeda Pharmaceutical Company Limited. Research Support; Self; AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis AG, Roche Pharma, Sanofi.